How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pseudomonas-aeruginosa-joint-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pseudomonas Aeruginosa Joint Infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pseudomonas Aeruginosa Joint Infection (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pseudomonas Aeruginosa Joint Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Ceftazidim	Ceftazidim	Tel-Aviv Sourasky Medical Center		Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Ciprofloxacine	Ciprofloxacine	Poitiers University Hospital		DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Pseudomonas Aeruginosa Joint Infection
Merck & Co. · 2 drugs in Pseudomonas Aeruginosa Joint Infection
Pai Holdings Pharm · 2 drugs in Pseudomonas Aeruginosa Joint Infection
Bristol-Myers Squibb · 1 drug in Pseudomonas Aeruginosa Joint Infection
Assistance Publique - Hôpitaux de Paris · 1 drug in Pseudomonas Aeruginosa Joint Infection
Tel-Aviv Sourasky Medical Center · 1 drug in Pseudomonas Aeruginosa Joint Infection
Poitiers University Hospital · 1 drug in Pseudomonas Aeruginosa Joint Infection
Bayer AG · 1 drug in Pseudomonas Aeruginosa Joint Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pseudomonas Aeruginosa Joint Infection:

Cite this brief

Drug Landscape (2026). Pseudomonas Aeruginosa Joint Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pseudomonas-aeruginosa-joint-infection. Accessed 2026-06-10.

Pseudomonas Aeruginosa Joint Infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing